Medical technology firm Waycen has entered into a sales agreement for its artificial intelligence (AI)-based medical solutions and health products with Saudi Arabia-based MegaMind.

Under the agreement, Waycen will introduce its AI gastrointestinal endoscopy software solution WAYMED Endo in the Middle East healthcare market using MegaMind IT Solution’s network.

The deal also includes the AI respiratory self-screening service WAYMED Cough.

MegaMind, a healthcare specialised company, has a network of 13 group hospitals across the Middle East. The firm is engaged in digital projects with more than 40 government and private healthcare institutions.

The sales agreement also includes collaboration for the development of future product lineups. This represents a new export opportunity in the Middle Eastern healthcare sector for K-Medical AI products.

The partnership is also expected to strengthen Waycen’s footprint in the region.

MegaMind CEO Hamza Batterjee said: “MegaMind has a mission and confidence to lead digital innovation in the Middle East healthcare market.”

MegaMind is also supporting digital innovation in Middle Eastern healthcare institutions by creating 15 to 25 data centres for Middle Eastern hospitals every year.

The firm is also collaborating with the government and healthcare organisations for remote consultations and digitalisation of medical data in these areas.

Waycen CEO Kim Kyungnam said: “With this agreement, MegaMind’s 13 hospitals in the Middle East will start utilising the artificial intelligence gastrointestinal endoscopy software, WAYMED Endo, within the year.”

WAYMED Endo is a medical device software that evaluates gastrointestinal endoscopic images in real-time using AI.

It works with endoscopes made by a variety of manufacturers, including Fujifilm, Pentax, and Olympus.

The software is also certified as a breakthrough device by South Korea’s Ministry of Food and Drug Safety.